Study of Camrelizumab in Combination With Apatinib Mesylate Plus Albumin-bound Paclitaxel and Cisplatin as the First Line Treatment of Recurrent or Metastatic, UnresectableHead and Neck Squamous Cell Carcinoma
This is a prospective, open-labelled study to evaluate the efficacy and safety of Camrelizumab in Combination With Apatinib mesylate Plus Albumin-bound paclitaxel and cisplatin as the First Line Treatment of Metastatic or Recurrent, UnresectableHead and Neck Squamous Cell Carcinoma. The objective response rate (ORR) will be evaluated as the primary endpoints.
Head and Neck Squamous Cell Carcinoma
DRUG: Camrelizumab+Apatinib mesylate+Albumin-bound paclitaxel+cisplatin
Objective Response Rate (CR+PR), Objective response rate (ORR) according to RECIST1.1, Time Frame: Up to 24 months
Overall survival (OS), Up to 24 months|Progression free survival (PFS), Progression free survival (PFS) according to RECIST 1.1, Up to 24 months
This is a prospective, open-labelled study to evaluate the efficacy and safety of Camrelizumab in Combination With Apatinib mesylate Plus Albumin-bound paclitaxel and cisplatin as the First Line Treatment of Metastatic or Recurrent, UnresectableHead and Neck Squamous Cell Carcinoma. The objective response rate (ORR) will be evaluated as the primary endpoints.